tradingkey.logo

Certara Inc

CERT
查看詳細走勢圖
7.230USD
-0.150-2.03%
收盤 02/06, 16:00美東報價延遲15分鐘
1.15B總市值
106.51本益比TTM

Certara Inc

7.230
-0.150-2.03%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.03%

5天

-17.75%

1月

-23.81%

6月

-35.79%

今年開始到現在

-17.93%

1年

-46.88%

查看詳細走勢圖

TradingKey Certara Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Certara Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在軟體與IT服務行業排名82/482位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為12.38。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Certara Inc評分

相關信息

行業排名
82 / 482
全市場排名
171 / 4521
所屬行業
軟體與IT服務

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看跌

Certara Inc亮點

亮點風險
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
估值合理
公司最新PE估值106.51,處於3年歷史合理位
機構加倉
最新機構持股185.12M股,環比增加0.54%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉26.58K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.19

分析師目標

基於 14 分析師
買入
評級
12.375
目標均價
+62.61%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Certara Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Certara Inc簡介

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
公司代碼CERT
公司Certara Inc
CEOFeehery (William F)
網址https://www.certara.com/
KeyAI